Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
44 studies found for:    triple negative breast cancer | Phase 3, 4
Show Display Options
Rank Status Study
1 Recruiting Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Biological: pembrolizumab;   Drug: capecitabine;   Drug: eribulin;   Drug: gemcitaine;   Drug: vinorelbine
2 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Normale Saline Solution
3 Not yet recruiting PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
Conditions: Breast Cancer;   Brain Metastasis
Intervention: Radiation: prophylactic cranial irradiation
4 Active, not recruiting Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Zoledronic acid
5 Not yet recruiting A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin
6 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
7 Recruiting Huaier Granule in Treating Women With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Huaier Granule
8 Active, not recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
9 Recruiting Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fu/epirubicin/CTX following Docetaxel;   Drug: Docetaxel/capecitabine followed by XEC
10 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)
Condition: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Nab-Paclitaxel;   Drug: Placebo
11 Recruiting Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: MSB0010718C
12 Recruiting Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention:
13 Recruiting Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Condition: Breast Cancer
Interventions: Drug: taxane plus carboplatin;   Drug: Taxane
14 Recruiting Adjuvant Treatment of EC Followed by wP and wPCb in Triple-Negative Breast Cancer
Condition: Breast Neoplasm
Interventions: Drug: Epirubicin plus Cyclophosphamide;   Drug: Paclitaxel;   Drug: Paclitaxel plus Carboplatin
15 Completed Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
16 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
17 Recruiting Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Condition: Invasive Ductal Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Abraxane;   Drug: MPDL3280A;   Procedure: Surgery;   Drug: Anthra
18 Recruiting Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Capecitabine
19 Completed A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: bevacizumab [Avastin]
20 Recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.